Sector News

J&J adds 200 jobs with new biopharma plant at site in Ireland

October 8, 2019
Life sciences

Johnson & Johnson’s Janssen has had biopharma operations in Ringaskiddy, Co. Cork for nearly 15 years. Now it has a new $350 million facility and added 200 jobs.

The official opening, which was announced by IDA Ireland, boosted the site’s size by 19,100 square meters (205,590 square feet).

“Our Ringaskiddy facility is an important part of our global manufacturing network and expanding our capabilities here will allow us to pursue innovative solutions …” Kathy Wengel, J&J’s chief global supply chain officer, said in a statement.

The company started on the €300 million project in 2017. The additions included expansion of an existing warehouse, laboratory and administration buildings, and expansion of the wastewater treatment plant to accommodate increased volumes.

At the time the company said the new plant would bolster capacity of APIs for drugs that treat “multiple myeloma, rheumatoid arthritis and Crohn’s disease.” While it didn’t specifically identify the products to be made there, J&J sells blockbuster Remicade for rheumatoid arthritis and Crohn’s disease, as well as Simponi for treating rheumatoid arthritis and Stelara for treating Crohn’s disease.

According to a new forecast from GlobalData, Stelara is expected to be the ninth-best selling drug globally in 2025 with $7.5 billion in sales.

By Eric Palmer

Source: Fierce Pharma

Related News

January 16, 2020

WuXi Bio buys Germany-based manufacturing plant from Bayer

Life sciences

LinkedIn Twitter FacebookShanghai, China-based Wuxi Biologics inked a deal with Germany’s Bayer to take over the operations of Bayer’s drug manufacturing factory in Leverkusen, Germany. It is also buying the […]

January 16, 2020

How will Amgen make its $13.4B Otezla buy pay off? New launches, for one, CEO says

Life sciences

LinkedIn Twitter FacebookWhen Amgen shelled out $13.4 billion late last year to pick up Celgene’s blockbuster immunology med Otezla, it made a calculated guess the drug had some untapped fuel […]

January 15, 2020

JPM: Want clues into Gilead’s M&A strategy? Check out last year’s Galapagos deal

Life sciences

LinkedIn Twitter FacebookAfter taking the reins at Gilead early last year, CEO Daniel O’Day’s been heading up the company long enough to understand what investors really want: more transparency and […]